BioSpace News Archive

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis.

GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain, and the United Kingdom, will launch ViewRay’s advanced MRIdian MRI-guided radiation therapy system at the Lee Health Regional Cancer Center on Monday, March 27, at its Fort Myers, FL location.

ANANDA Scientific Inc. today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluating Nantheia™ A1002N5S , an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary Liquid Structure™ delivery technology as a potential treatment for Social Anxiety Disorder (SAD).

Bicycle Therapeutics plc today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets.

Gelesis Holdings, Inc. today reported financial results for the year ended December 31, 2022.

Switch Therapeutics today announced the appointments of Craig Blanchette, Ph.D., as Senior Vice President, Research and Michael Wolfe as Senior Vice President, Finance and Operations, effective immediately.

Elucid, Inc. has hired Andrew Miller as its chief technology officer (CTO).

Silence Therapeutics plc today announced it will be acquiring back exclusive worldwide rights to two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals.

Harrow, a leading U.S. eyecare pharmaceutical company, announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P.

Silence Therapeutics plc today announced the appointment of Steven Romano, MD, as incoming Chief Medical Officer and Head of Research and Development.